NIH Research Response to the Threat of Bioterrorism

- Biodefense Research Activities
- Coordination of Research Activities
- Research and Development Priorities Based on Threat Assessment



NIAID Strategic Plan for Biodefense Research





NIAID Biodefense Research Agenda for CDC Category A Agents





NIAID Biodefense Research Agenda for Category B and C Priority Pathogens





NIAID Biodefense Research Agenda for CDC Category A Agents









NIAID Biodefense Research Agenda for Category B and C Priority Pathogens


Progress Report






January 2003

Expansion of Biodefense Research Capacity



- National Biocontainment Laboratories (BSL4) 2
- Regional Biocontainment Laboratories (BSL3) 9
- Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research 8
- New NIH Facilities 4

NIH Biodefense Research and Development Pathway



Countermeasure Development

- New and Improved Vaccines (smallpox, anthrax, Ebola, tularemia, plague)
- Therapies (smallpox and anthrax therapeutics, botulism antitoxins)
- Diagnostics








Coordination of Biodefense Activities

NIH

NIH Biodefense Research Coordinating Committee



NIH Institutes and Centers


DHHS

Office of the Assistant Secretary for Public Health Emergency Preparedness



Federal Government

Homeland Security Council and National Security Council



Federal Agencies

- DHS
- HHS
- DOD
- Other relevant agencies

Research and Development Priorities Based on Threat Assessment

CDC Category A, B, and C agents

Department of Homeland Security (DHS)